J&J Innovation expands company incubation strategy

Johnson & Johnson Innovation has confirmed its company incubation strategy is being expanded.

It will now include a multi-faceted initiative in Europe designed to identify early-stage businesses that are actively pursuing research that can potentially transform human health.

The firm is collaborating with Janssen Pharmaceutical NV under the banner of Johnson & Johnson Innovation, JLINX (JLINX) and will attempt to nurture these companies and offer start-ups flexible ways to grow and collaborate across Europe's life science ecosystem.

A dedicated JLINX facility is being set up at the Janssen campus in Beerse, Belgium and is expected to be up and running by the summer.

Paul Stoffels, chief scientific officer and worldwide chairman of pharmaceuticals at Johnson & Johnson, commented: "The mission of Johnson & Johnson Innovation is to identify and advance the best science – internal or external – to bring healthcare solutions to patients and consumers around the world."

He added that it is confident JLINX will create a vibrant ecosystem of start-ups and entrepreneurs with access to the world-class expertise and technology.